ReviewBiomedicines2025
Telomeres, Telomerase, and Curcumin: A New Frontier in Cancer Therapy: A Narrative Review.
Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dyskerin dysfunction in cancer development: from telomere dysregulation to immune deficiency.American journal of cancer research · 2026Review
- Association of Telomere Length with Ovarian Cancer Risk and Survival: A Systematic Review and Meta -analysis.Journal of mid-life healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomeres, which serve as protective ends on chromosomes, and telomerase, the enzyme that preserves telomere length, play crucial roles in ensuring genomic stability and delaying cellular aging. Dysregulation of these proteins is a key characteristic of cancer development. This review aimed to explore the complex processes involved in telomere and telomerase dysregulation in cancer and evaluate the therapeutic potential of curcumin. Curcumin has attracted significant interest due to its anticancer, antioxidant, and anti-inflammatory properties. Curcumin modulates telomere dynamics and inhibits telomerase activity, leading to cancer cell senescence and telomere shortening. Curcumin downregulates human telomerase reverse transcriptase expression and reduces telomerase activity in various cancer cell lines. Despite its potential, its clinical use is restricted by its poor water solubility and limited bioavailability. This review underscores the critical role of telomere/telomerase dysregulation in cancer and highlights curcumin as a promising modulator of these pathways, thereby offering potential novel strategies for cancer treatment. This review integrates the literature published up to September 2025 to ensure the inclusion of the most recent advances in curcumin-related telomerase modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.